J4137

Sigma-Aldrich

JS-K

≥97%

Synonym(s):
O2-(2,4-Dinitrophenyl) 1-(4-ethoxycarbonyl)piperazin-1-yldiazen-1-ium-1,2-diolate
Empirical Formula (Hill Notation):
C13H16N6O8
CAS Number:
Molecular Weight:
384.30
MDL number:
PubChem Substance ID:
Pricing and availability is not currently available.

Quality Level

assay

≥97%

storage condition

desiccated

solubility

DMSO: soluble 9.3 mg/mL
H2O: insoluble

shipped in

dry ice

storage temp.

−20°C

SMILES string

CCOC(=O)N1CCN(CC1)\N+(O-)=N\Oc2ccc(cc2N+(O-)=O)N+(O-)=O

InChI

1S/C13H16N6O8/c1-2-26-13(20)15-5-7-16(8-6-15)19(25)14-27-12-4-3-10(17(21)22)9-11(12)18(23)24/h3-4,9H,2,5-8H2,1H3/b19-14-

InChI key

DNJRNBYZLPKSHV-RGEXLXHISA-N

Packaging

5 mg in glass bottle
25 mg in poly bottle

Biochem/physiol Actions

JS-K belongs to the class of diazeniumdiolate prodrug. It generates nitric oxide when metabolized by glutathione S-transferases (GST), which ensures optimal activity of JS-K. It has tumor growth inhibition action in human prostate cancer and leukemia.
Nitric oxide donor; antiproliferative.

Features and Benefits

This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more.

Legal Information

Covered by US Patent No 6,610,660
LOPAC is a registered trademark of Sigma-Aldrich Co. LLC

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves

RIDADR

NONH for all modes of transport

WGK Germany

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
Martin Laschak et al.
BMC cancer, 12, 130-130 (2012-04-03)
Nitric oxide (NO) and its oxidative reaction products have been repeatedly shown to block steroid receptor function via nitrosation of zinc finger structures in the DNA-binding domain (DBD). In consequence NO-donors could be of special interest for the treatment of...
Ray Dong et al.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 88, 367-373 (2017-01-26)
JS-K is a novel anticancer nitric oxide (NO) prodrug effective against a variety of cancer cells, including the inhibition of AM-1 hepatoma cell growth in rats. To further evaluate anticancer effects of JS-K, human hepatoma Hep3B cells were treated with...
Zhengyun Liu et al.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 92, 989-997 (2017-06-14)
Hepatocellular carcinoma (HCC) is the most important cause of cancer-related death, and 85% of HCC is caused by chronic HBV infection, the prognosis of patients and the reduction of HBV DNA levels remain unsatisfactory. JS-K, a nitric oxide-releasing diazeniumdiolates, is...
Zeqing Song et al.
Oncology reports, 41(6), 3475-3487 (2019-04-20)
Lung cancer is one of the most common malignancies worldwide, with high mortality and morbidity rates. O2‑​(2,4‑​dinitrophenyl)‑1‑​[(4‑ethoxycarbonyl)piperazin‑1‑yl]diazen‑1‑ium‑1,2‑diolate (JS‑K) is a potent anticancer agent that acts against a subset of human non‑small cell lung cancer (NSCLC) cell lines; however, the underlying...
Zile Huang et al.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 107, 1385-1392 (2018-09-28)
JS-K, (O2-(2, 4-dinitrophenyl) 1-[(4-ethoxycarbonyl) piperazin-1-yl] diazen 1-ium-1, 2-diolate), is a novel diazeniumdiolate-based nitric oxide donor prodrug. The present study investigated the relationship between reactive oxygen species (ROS) elevation, Ca2+ overload and mitochondrial disruption in JS-K-induced apoptosis. JS-K could significantly inhibit...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.